Research Pharmacy

研究药房

• 批准号: 8975654
• 负责人: Sylvia Bartel
• 金额: $ 22.54万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至 2016-12-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8975654
• 关键词: Cancer Center; Cancer Center Support Grant; Clinical Investigator; Clinical Research; Clinical Trials; Comprehensive Cancer Center; Dana-Farber Cancer Institute; Data; Ensure; Focus Groups; Formulation; Fostering; Funding; Hospitals; Institution; Instruction; Investigation; Malignant Neoplasms; Monitor; Performance; Pharmaceutical Preparations; Pharmacists; Pharmacy facility; Physician Executives; Policies; Procedures; Process; Protocols documentation; Regulation; Reporting; Research; Research Personnel; Research Support; Resource Sharing; Review Committee; Safety; Site; System; Therapeutics Committee; Time; United States National Institutes of Health; Work; clinical investigation; experience; inter-institutional; meetings; member; operation; programs; quality assurance

The Research Pharmacy Core has a well-developed system for the monitoring, coordination, and support of research pharmacy activities at DF/HCC member institutions. This facility has been approved and funded by the CCSG since 2004, when it received excellent merit. The Core assures consistency in policies across the sites (including policies relating to the receipt, storage, formulation, and dispensation of investigational agents), facilitates best practices, and monitors perfonnance through a quality assurance program coordinated through the inter-institutional Research Pharmacy Core Committee. The Research Pharmacy participates in the DF/HCC Scientific Review and Monitoring Committees (PRMS) and Data and Safety Monitoring (DSM) program, as well as other relevant Cancer Center clinical trials oversight, monitoring, and policy initiatives.

研究药房核心具有一个完善的系统，用于监视，协调和支持 DF/HCC成员机构的研究药房活动。该设施已获得批准和资助 CCSG自2004年以来获得了出色的功绩。核心确保了整个政策的一致性 站点（包括与收据，存储，配方有关的政策 代理商），促进最佳实践，并通过质量保证计划监视完善 通过机构间研究药房核心委员会协调。研究药房 参加DF/HCC科学评论和监测委员会（PRMS）以及数据和安全 监测（DSM）计划以及其他相关癌症中心临床试验监督，监测和 政策计划。